FOCUS ISSUE: DRUG-ELUTING STENTS: TAXUS-IV
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus
The TAXUS-IV trial
James B. Hermiller, MD, FACC*,1,
Albert Raizner, MD, FACC ,
Louis Cannon, MD, FACC ,
Paul A. Gurbel, MD, FACC ,
Michael A. Kutcher, MD, FACC||,
S. Chiu Wong, MD, FACC¶,
Mary E. Russell, MD#,2,
Stephen G. Ellis, MD, FACC**,1,
Roxana Mehran, MD, FACC,
Gregg W. Stone, MD, FACC,1,* TAXUS-IV Investigators
* St. Vincent’s Hospital, Indianapolis, Indiana
Cardiac Cath Lab Research Center, Houston, Texas
St. Mary’s Medical Center, Saginaw, Michigan
Sinai Hospital of Baltimore, Baltimore, Maryland
|| Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
¶ New York Presbyterian Hospital, New York, New York
# Boston Scientific Corp., Natick, Massachusetts
** Cleveland Clinic Foundation, Cleveland, Ohio
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Manuscript received June 28, 2004;
revised manuscript received October 18, 2004,
accepted October 19, 2004.
* Reprint requests and correspondence: Dr. Gregg W. Stone, Cardiovascular Research Foundation, 55 East 59th Street, 6th Floor, New York, New York 10022. (Email: gstone{at}crf.org).
OBJECTIVES: We sought to determine the safety and efficacy of polymer-regulated site-specific delivery of paclitaxel in patients with diabetes mellitus undergoing stent implantation.
BACKGROUND: Percutaneous coronary intervention in patients with diabetes is associated with high rates of restenosis and repeat revascularization due to excessive neointimal proliferation, a process that may be blunted with the site-specific delivery of paclitaxel.
METHODS: In the TAXUS-IV trial, 1,314 patients were prospectively randomized to the slow rate-release polymer-based paclitaxel-eluting TAXUS stent or the bare-metal EXPRESS stent (Boston Scientific Corp., Natick, Massachusetts). Medically treated diabetes was present in 318 patients (24%), 105 of whom required insulin.
RESULTS: Among patients with diabetes, the TAXUS stent, compared to the bare-metal stent, reduced the rate of 9-month binary angiographic restenosis by 81% (6.4% vs. 34.5%, p < 0.0001), and reduced the 12-month rates of target lesion revascularization by 65% (7.4% vs. 20.9%, p = 0.0008), target vessel revascularization by 53% (11.3% vs. 24%, p < 0.004), and composite major adverse cardiac events by 44% (15.6% vs. 27.7%, p = 0.01). The one-year rates of cardiac death (1.9% vs. 2.5%), myocardial infarction (3.2% vs. 6.4%), and subacute thrombosis (0.6% vs. 1.2%) were comparable between the paclitaxel-eluting and control stents, respectively. In the insulin-requiring subgroup, the TAXUS stent reduced angiographic restenosis by 82% (7.7% vs. 42.9%, p = 0.0065), and reduced the one-year rate of target lesion revascularization by 68% (6.2% vs. 19.4%, p = 0.07), a relative reduction similar to patients without diabetes.
CONCLUSIONS: The site-specific delivery of paclitaxel after coronary stent implantation is highly effective in reducing clinical and angiographic restenosis in patients with diabetes mellitus.
|
Abbreviations and Acronyms
| | MACE = major adverse cardiac events | | MI = myocardial infarction | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
G. S. Aldea, N. A. Mokadam, R. Melford Jr, D. Stewart, C. Maynard, M. Reisman, and R. Goss
Changing Volumes, Risk Profiles, and Outcomes of Coronary Artery Bypass Grafting and Percutaneous Coronary Interventions.
Ann. Thorac. Surg.,
June 1, 2009;
87(6):
1828 - 1838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, Z. Zheng, B. Xu, S. Zhang, W. Li, R. Gao, and S. Hu
Comparison of Drug-Eluting Stents and Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Disease: Three-Year Follow-Up Results From a Single Institution
Circulation,
April 21, 2009;
119(15):
2040 - 2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mahmud, J. A. Ormiston, M. A. Turco, J. J. Popma, N. J. Weissman, C. D. O'Shaughnessy, T. Mann, J. J. Hall, T. F. McGarry, L. A. Cannon, et al.
TAXUS Liberte Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus: Results From the TAXUS ATLAS Program
J. Am. Coll. Cardiol. Intv.,
March 1, 2009;
2(3):
240 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Garg, S.-L. T. Normand, T. S. Silbaugh, R. E. Wolf, K. Zelevinsky, A. Lovett, M. R. Varma, Z. Zhou, and L. Mauri
Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus: Results From the Massachusetts Data Analysis Center Registry
Circulation,
November 25, 2008;
118(22):
2277 - 2285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. O. Jensen, M. Maeng, P. Thayssen, E. H. Christiansen, K. N. Hansen, A. Galloe, H. Kelbaek, J. F. Lassen, and L. Thuesen
Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial
Eur. Heart J.,
November 2, 2008;
29(22):
2733 - 2741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Stettler, S. Allemann, S. Wandel, A. Kastrati, M. C. Morice, A. Schomig, M. E Pfisterer, G. W Stone, M. B Leon, J. S. d. Lezo, et al.
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
BMJ,
August 29, 2008;
337(aug29_3):
a1331 - a1331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria
Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
J. Am. Coll. Cardiol.,
June 24, 2008;
51(25):
2385 - 2395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Hannan, M. Racz, D. R. Holmes, G. Walford, S. Sharma, S. Katz, R. H. Jones, and S. B. King III
Comparison of Coronary Artery Stenting Outcomes in the Eras Before and After the Introduction of Drug-Eluting Stents
Circulation,
April 22, 2008;
117(16):
2071 - 2078.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Billinger, J. Beutler, K. R. Taghetchian, A. Remondino, P. Wenaweser, S. Cook, M. Togni, C. Seiler, C. Stettler, F. R. Eberli, et al.
Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients
Eur. Heart J.,
March 2, 2008;
29(6):
718 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. E. Hellings, F. L. Moll, J.-P. P. M. De Vries, R. G. A. Ackerstaff, K. A. Seldenrijk, R. Met, E. Velema, W. J. M. Derksen, D. P. V. De Kleijn, and G. Pasterkamp
Atherosclerotic Plaque Composition and Occurrence of Restenosis After Carotid Endarterectomy
JAMA,
February 6, 2008;
299(5):
547 - 554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Hannan, C. Wu, G. Walford, A. T. Culliford, J. P. Gold, C. R. Smith, R. S.D. Higgins, R. E. Carlson, and R. H. Jones
Drug-Eluting Stents vs. Coronary-Artery Bypass Grafting in Multivessel Coronary Disease
N. Engl. J. Med.,
January 24, 2008;
358(4):
331 - 341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Brown, T. M. Sundt III, and B. J. Gersh
Indications for Revascularization
Card. Surg. Adult,
January 1, 2008;
3(2008):
551 - 572.
[Full Text]
|
|
|
|
|
|
|
J. M. Wilson and J. T. Willerson
Myocardial Revascularization with Percutaneous Devices
Card. Surg. Adult,
January 1, 2008;
3(2008):
573 - 598.
[Full Text]
|
|
|
|
|
|
|
M. Togni, S. Eber, J. Widmer, M. Billinger, P. Wenaweser, S. Cook, R. Vogel, C. Seiler, F. R. Eberli, W. Maier, et al.
Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX Trial
J. Am. Coll. Cardiol.,
September 18, 2007;
50(12):
1123 - 1131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part II: Unsettled Issues
Circulation,
August 21, 2007;
116(8):
961 - 968.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Marzocchi, F. Saia, G. Piovaccari, A. Manari, E. Aurier, A. Benassi, A. Cremonesi, G. Percoco, E. Varani, P. Magnavacchi, et al.
Long-Term Safety and Efficacy of Drug-Eluting Stents: Two-Year Results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) Multicenter Registry
Circulation,
June 26, 2007;
115(25):
3181 - 3188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-P. B.-L. Rocca, C. Kaiser, M. Pfisterer, and on behalf of the BASKET Investigators
Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)
Eur. Heart J.,
March 2, 2007;
28(6):
719 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Berry, J.-C. Tardif, and M. G. Bourassa
Coronary Heart Disease in Patients With Diabetes: Part II: Recent Advances in Coronary Revascularization
J. Am. Coll. Cardiol.,
February 13, 2007;
49(6):
643 - 656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Daemen, H. M. Garcia-Garcia, N. Kukreja, F. Imani, P. P.T. de Jaegere, G. Sianos, R. T. van Domburg, and P. W. Serruys
The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus
Eur. Heart J.,
January 1, 2007;
28(1):
26 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ben-Gal, Y. Moshkovitz, N. Nesher, G. Uretzky, R. Braunstein, A. Hendler, E. Zivi, I. Herz, and R. Mohr
Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Patients with Diabetes Mellitus
Ann. Thorac. Surg.,
November 1, 2006;
82(5):
1692 - 1697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kastrati, A. Dibra, J. Mehilli, S. Mayer, S. Pinieck, J. Pache, J. Dirschinger, and A. Schomig
Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents
Circulation,
May 16, 2006;
113(19):
2293 - 2300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
April 18, 2006;
47(8):
1689 - 1706.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. De Luca, H. Suryapranata, J. Timmer, J. P. Ottervanger, A. W.J. van't Hof, J. C.A. Hoorntje, J.-H. Dambrink, A.T. M. Gosselink, and M.-J. de Boer
Impact of Routine Stenting on Clinical Outcome in Diabetic Patients Undergoing Primary Angioplasty for ST-Segment Elevation Myocardial Infarction
Diabetes Care,
April 1, 2006;
29(4):
920 - 923.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Seabra-Gomes
Percutaneous coronary interventions with drug eluting stents for diabetic patients.
Heart,
March 1, 2006;
92(3):
410 - 419.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas
Highlights of the Year in JACC 2005
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
184 - 202.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Thomas
Are drug eluting stents really worth the money?
Heart,
January 1, 2006;
92(1):
5 - 7.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sabate, P. Jimenez-Quevedo, D. J. Angiolillo, J. A. Gomez-Hospital, F. Alfonso, R. Hernandez-Antolin, J. Goicolea, C. Banuelos, J. Escaned, R. Moreno, et al.
Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial
Circulation,
October 4, 2005;
112(14):
2175 - 2183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dibra, A. Kastrati, J. Mehilli, J. Pache, H. Schuhlen, N. von Beckerath, K. Ulm, R. Wessely, J. Dirschinger, A. Schomig, et al.
Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients
N. Engl. J. Med.,
August 18, 2005;
353(7):
663 - 670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes, R. E. Kuntz, L. Mauri, and M. W. Krucoff
Surrogates, substudies, and real clinical end points in trials of drug-eluting stents
J. Am. Coll. Cardiol.,
April 19, 2005;
45(8):
1206 - 1212.
[Full Text]
[PDF]
|
|
|
|
